Metraipolis › archive › dc_3930875edaf2

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity… — Europe PMC PMID:42389639

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42389639
DOI
10.3389/fcvm.2026.1849205
License (as archived)
solo-consultazione
Archived
2026-10-19T08:45:01.782Z
SHA-256 of the archived text
1b0377ce864c12377743477c4d9bd7b14cd3543f6921cee84db31e2be417ff6d
Stable URL of this page
https://metraipolis.com/documento/dc_3930875edaf2

How to cite

Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity… — Europe PMC PMID:42389639 — Europe PMC (en), https://europepmc.org/article/MED/42389639 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3930875edaf2 (Metraipolis archive dc_3930875edaf2, sha256 1b0377ce864c12377743477c4d9bd7b14cd3543f6921cee84db31e2be417ff6d)
BibTeX
@misc{dc3930875edaf2,
  title = {Long-term efficacy and renal safety of SGLT2 inhibitors in patients with heart failure and advanced chronic kidney disease (stage 4): a propensity… — Europe PMC PMID:42389639},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42389639},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3930875edaf2; sha256 1b0377ce864c12377743477c4d9bd7b14cd3543f6921cee84db31e2be417ff6d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42389639. Agents can read the archived copy with the MCP tool read_document.